CO2023005736A2 - Moduladores del regulador de la conductancia transmembrana de la fibrosis quística - Google Patents

Moduladores del regulador de la conductancia transmembrana de la fibrosis quística

Info

Publication number
CO2023005736A2
CO2023005736A2 CONC2023/0005736A CO2023005736A CO2023005736A2 CO 2023005736 A2 CO2023005736 A2 CO 2023005736A2 CO 2023005736 A CO2023005736 A CO 2023005736A CO 2023005736 A2 CO2023005736 A2 CO 2023005736A2
Authority
CO
Colombia
Prior art keywords
modulators
conductance regulator
transmembrane conductance
cystic fibrosis
fibrosis transmembrane
Prior art date
Application number
CONC2023/0005736A
Other languages
English (en)
Inventor
Thomas Cleveland
Fabrice Jean Denis Pierre
Corey Don Anderson
Timothy Richard Coon
Peter Grootenhuis (Deceased)
Ruah Sara Sabina Hadida
Jason Mccartney
Mark Thomas Miller
Jinglan Zhou
Alexander Russell Abela
Sunny Abraham
Vijayalaksmi Arumugam
Jaclyn Chau
Jeremy Clemens
Timothy A Dwight
Bryan A Frieman
Yoshihiro Ishihara
Paul Krenitsky
Alina Silina
Lev Tyler Dewey Fanning
Lino Valdez
Joe A Tran
Andrew Dinh
Original Assignee
Vertex Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharma filed Critical Vertex Pharma
Publication of CO2023005736A2 publication Critical patent/CO2023005736A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D515/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D515/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D515/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D515/14—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Oscillators With Electromechanical Resonators (AREA)
  • Amplifiers (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Esta descripción proporciona moduladores del regulador de la conductancia transmembrana de la fibrosis quística (CFTR) que tienen la estructura central (I), composiciones farmacéuticas que contienen al menos un modulador de este tipo, métodos de tratamiento de enfermedades mediadas por CFTR, que incluyen fibrosis quística, mediante el uso de tales moduladores y composiciones farmacéuticas, composiciones farmacéuticas de combinaciones y terapias combinadas, y procesos y productos intermediarios para producir tales moduladores.
CONC2023/0005736A 2020-10-07 2023-05-05 Moduladores del regulador de la conductancia transmembrana de la fibrosis quística CO2023005736A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063088799P 2020-10-07 2020-10-07
PCT/US2021/053861 WO2022076625A1 (en) 2020-10-07 2021-10-06 Modulators of cystic fibrosis transmembrane conductance regulator

Publications (1)

Publication Number Publication Date
CO2023005736A2 true CO2023005736A2 (es) 2023-09-08

Family

ID=78536577

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2023/0005736A CO2023005736A2 (es) 2020-10-07 2023-05-05 Moduladores del regulador de la conductancia transmembrana de la fibrosis quística

Country Status (19)

Country Link
US (1) US20240018161A1 (es)
EP (1) EP4225447A1 (es)
JP (1) JP2023545762A (es)
KR (1) KR20230104619A (es)
CN (1) CN116670143A (es)
AR (1) AR123710A1 (es)
AU (1) AU2021356651A1 (es)
BR (1) BR112023006470A2 (es)
CA (1) CA3197173A1 (es)
CL (1) CL2023001013A1 (es)
CO (1) CO2023005736A2 (es)
CR (1) CR20230197A (es)
DO (1) DOP2023000065A (es)
IL (1) IL301756A (es)
MX (1) MX2023004073A (es)
PE (1) PE20231951A1 (es)
TW (1) TW202229296A (es)
UY (1) UY39459A (es)
WO (1) WO2022076625A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023150236A1 (en) 2022-02-03 2023-08-10 Vertex Pharmaceuticals Incorporated Methods of preparing and crystalline forms of (6a,12a)-17-amino-12-methyl-6,15-bis(trifluoromethyl)-13,19-dioxa-3,4,18-triazatricyclo[ 12.3.1.12,5]nonadeca-1(18),2,4,14,16-pentaen-6-ol
TW202333699A (zh) 2022-02-03 2023-09-01 美商維泰克斯製藥公司 囊腫纖維化之治療方法
WO2023196429A1 (en) * 2022-04-06 2023-10-12 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
WO2023224931A1 (en) 2022-05-16 2023-11-23 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis
WO2024056798A1 (en) 2022-09-15 2024-03-21 Idorsia Pharmaceuticals Ltd Macrocyclic cftr modulators
WO2024056791A1 (en) 2022-09-15 2024-03-21 Idorsia Pharmaceuticals Ltd Combination of macrocyclic cftr modulators with cftr correctors and / or cftr potentiators
WO2024056779A1 (en) 2022-09-15 2024-03-21 Idorsia Pharmaceuticals Ltd Crystalline form of (3s,7s,10r,13r)-13-benzyl-20-fluoro-7-isobutyl-n-(2-(3-methoxy-1,2,4-oxadiazol-5-yl)ethyl)-6,9-dimethyl-1,5,8,11-tetraoxo-10-(2,2,2-trifluoroethyl)-1,2,3,4,5,6,7,8,9,10,11,12,13,14-tetradecahydro-[1]oxa[4,7,10,14]tetraazacycloheptadecino[16,17-f]quinoline-3-carboxamide

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100074949A1 (en) 2008-08-13 2010-03-25 William Rowe Pharmaceutical composition and administration thereof
RS53895B1 (en) 2004-06-24 2015-08-31 Vertex Pharmaceuticals Incorporated ATP-BINDING CASSETTE TRANSPORT MODULATORS
PT1945632E (pt) 2005-11-08 2013-12-24 Vertex Pharma Moduladores heterocíclicos de transportadores de cassete de ligação a atp
PL3219705T3 (pl) 2005-12-28 2020-08-10 Vertex Pharmaceuticals Incorporated Kompozycje farmaceutyczne amorficznych postaci n-[2,4-bis(1,1-dimetyloetylo)-5-hydroksyfenylo]-1,4-dihydro-4-oksochinolino-3-karboksyamidu
US7645789B2 (en) 2006-04-07 2010-01-12 Vertex Pharmaceuticals Incorporated Indole derivatives as CFTR modulators
WO2007134279A2 (en) 2006-05-12 2007-11-22 Vertex Pharmaceuticals Incorporated Compositions of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
SI2639224T1 (sl) 2007-12-07 2016-12-30 Vertex Pharmaceuticals Incorporated Postopek za pripravo cikloalkilkarboksiamido-piridinskih benzojskih kislin
DK3170818T3 (da) 2007-12-07 2020-04-14 Vertex Pharma Faste former af 3-(6-(1-(2,2-difluorbenzo[d][1,3]dioxol-5-yl) cyclopropancarboxamido)-3-methylpyridin-2-yl)benzoesyre
RS56894B1 (sr) 2008-08-13 2018-04-30 Vertex Pharma Farmaceutska kompozicija n-[2,4-bis(1,1-dimetiletil)-5-hidroksifenil]-1,4-dihidro-4-oksohinolin-3-karboksamida i njeno ordiniranje
AR073709A1 (es) 2008-09-29 2010-11-24 Vertex Pharma Unidades de dosis de acido 3-(6-(1-(2,2-difluorobenzeno (d) (1,3) dioxol-5-il) ciclopropancarboxamido)-3-metilpiridin-2-il) benzoico
CN108117546A (zh) 2008-11-06 2018-06-05 弗特克斯药品有限公司 Atp-结合盒转运蛋白调节剂
SI2821400T1 (en) 2009-03-20 2018-02-28 Vertex Pharmaceuticals Incorporated A process for the manufacture of a transmembrane conductivity regulator in cystic fibrosis
EP4253381A3 (en) 2010-03-25 2023-11-01 Vertex Pharmaceuticals Incorporated Solid forms of (r)-1-(2,2-difluorobenzo[d][1,3]d ioxol-5-yl)-n-(1-(2,3-dihydroxyp ropyl)-6-fluoro-2-(1-hydroxy- 2-methylpropan-2-yl)-1h-indol- 5-yl) cyclopropanecarboxamide
AU2011237368B2 (en) 2010-04-09 2015-07-23 Ekso Bionics Exoskeleton load handling system and method of use
CN105130948A (zh) 2010-04-22 2015-12-09 弗特克斯药品有限公司 制备环烷基甲酰胺基-吲哚化合物的方法
EP2560649A1 (en) 2010-04-22 2013-02-27 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions and administrations thereof
RU2013113627A (ru) 2010-08-27 2014-10-10 Вертекс Фармасьютикалз Инкорпорейтед Фармацевтическая композиция и ее введения
WO2012158885A1 (en) 2011-05-18 2012-11-22 Concert Pharmaceuticals Inc. Deuterated derivatives of ivacaftor
HUE047354T2 (hu) 2011-05-18 2020-04-28 Vertex Pharmaceuticals Europe Ltd Ivacaftor deuterizált származékai
EP2819670A1 (en) 2012-02-27 2015-01-07 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administration thereof
CA2878057A1 (en) 2012-07-16 2014-01-23 Rossitza Gueorguieva Alargova Pharmaceutical compositions of (r)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-n-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl) cyclopropanecarboxamide and administration thereof
LT2914248T (lt) 2012-11-02 2018-11-26 Vertex Pharmaceuticals Incorporated Farmacinės kompozicijos, skirtos cftr medijuotų ligų gydymui
MY183582A (en) 2012-11-19 2021-02-26 Vertex Pharmaceuticals Europe Ltd Deuterated cftr potentiators
RS57476B9 (sr) 2014-04-15 2021-10-29 Vertex Pharma Farmaceutske kompozicije za lečenje bolesti posredovanih transmembranskim regulatorom provodljivosti cistične fibroze
US20180353500A1 (en) 2015-09-21 2018-12-13 Vertex Pharmaceuticals (Europe) Limited Administration of deuterated cftr potentiators
WO2018080591A1 (en) 2016-10-27 2018-05-03 Vertex Pharmaceuticals (Europe) Limited Methods of treatment with deuterated cftr potentiators
SI3752510T1 (sl) * 2018-02-15 2023-03-31 Vertex Pharmaceuticals Incorporated Makrocikli kot modulatorji regulatorja transmembranske prevodnosti pri cistični fibrozi, farmacevtski sestavki iz le-teh, njihova uporaba pri zdravljenju cistične fibroze in postopek za njihovo proizvodnjo
UY38630A (es) * 2019-04-03 2020-10-30 Vertex Pharma Agentes moduladores del regulador de la conductancia transmembrana de la fibrosis quística
CN114599657A (zh) * 2019-08-14 2022-06-07 弗特克斯药品有限公司 Cftr调节剂的结晶形式

Also Published As

Publication number Publication date
CL2023001013A1 (es) 2023-11-24
CA3197173A1 (en) 2022-04-14
EP4225447A1 (en) 2023-08-16
BR112023006470A2 (pt) 2023-09-26
DOP2023000065A (es) 2023-07-09
JP2023545762A (ja) 2023-10-31
WO2022076625A1 (en) 2022-04-14
IL301756A (en) 2023-05-01
PE20231951A1 (es) 2023-12-06
CN116670143A (zh) 2023-08-29
KR20230104619A (ko) 2023-07-10
MX2023004073A (es) 2023-07-05
AR123710A1 (es) 2023-01-04
TW202229296A (zh) 2022-08-01
AU2021356651A1 (en) 2023-05-18
UY39459A (es) 2022-05-31
US20240018161A1 (en) 2024-01-18
CR20230197A (es) 2023-07-06

Similar Documents

Publication Publication Date Title
CO2023005736A2 (es) Moduladores del regulador de la conductancia transmembrana de la fibrosis quística
DOP2023000066A (es) Moduladores del regulador de la conductancia transmembrana de la fibrosis quística
CO2022002749A2 (es) Moduladores del regulador de conductancia transmembrana de la fibrosis quística
UY39374A (es) Moduladores del regulador de la conductancia transmembrana de la fibrosis quística
DOP2023000067A (es) Moduladores del regulador de la conductancia transmembrana de la fibrosis quística
CO2019007129A2 (es) Modulador del regulador de conductancia transmembrana de fibrosis quística, composiciones farmacéuticas, métodos de tratamiento y proceso para producir el modulador
CL2019000827A1 (es) Modulador del regulador de conductancia de transmembrana de fibrosis quística, composiciones farmacéuticas, métodos de tratamiento y proceso para producir el modulador.
UY39456A (es) Moduladores del regulador de conductancia transmembranario de la fibrosis quística
UY39458A (es) Moduladores del regulador de conductancia transmembranario de la fibrosis quística
UY39461A (es) Moduladores del regulador de conductancia transmembranario de la fibrosis quística
UY39455A (es) Moduladores del regulador de conductancia transmembranario de la fibrosis quística
CL2021000741A1 (es) Composiciones plaguicidas sinérgicas y métodos para distribución de ingredientes activos insecticidas
CL2019002671A1 (es) Compuestos de pirimidinil-pyridiloxi-naftil y métodos para tratar enfermedades y trastornos relacionados con ire1.
NI201700031A (es) Moduladores de pirrolopiridina de rorc2 sustituidos con metilo y trifluorometilo y métodos de uso de los mismos.
CL2019001014A1 (es) Métodos de tratamiento de afecciones relacionadas con la inflamación utilizando moduladores metabólicos y anti inflamatorios pluripotentes.
CL2022001178A1 (es) Ligandos de la pseudoquinasa tyk2
CL2021002078A1 (es) Composiciones y métodos para la administración de polipéptidos cftr.
CO2023013465A2 (es) Composiciones y métodos para inhibir cetohexoquinasa (khk)
BR112021019102A2 (pt) Composições e métodos para tratamento de fibrose cística
BR112018006431A2 (pt) uma composição farmacêutica bactericida e virucida
CL2022001476A1 (es) Uso de reboxetina para tratar los trastornos del sistema nervioso
PE20230181A1 (es) Uso de reboxetina para tratar los trastornos del sistema nervioso
CL2009000117A1 (es) Compuestos derivados de carboxamida o carboxatioamida azabiciclica, moduladores trpv1; composicion farmaceutica que los contiene; proceso de preparacion de los compuestos e intermediarios; y uso en el tratamiento del dolor, inflamacion, trastornos metabolicos , entre otras.